Michael Becker to Hyperuricemia
This is a "connection" page, showing publications Michael Becker has written about Hyperuricemia.
Connection Strength
4.295
-
Summary of the 2015 Purine and Pyrimidine Society/Purine Metabolic Patients Association H. Anne Simmonds Memorial Lecture. Nucleosides Nucleotides Nucleic Acids. 2016 Dec; 35(10-12):502-506.
Score: 0.542
-
Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease. Curr Med Res Opin. 2015; 31 Suppl 2:9-14.
Score: 0.474
-
Urate transporters: transforming the face of hyperuricemia and gout. J Rheumatol. 2014 Oct; 41(10):1910-2.
Score: 0.464
-
Long-term management of gout: nonpharmacologic and pharmacologic therapies. Rheum Dis Clin North Am. 2014 May; 40(2):357-74.
Score: 0.447
-
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects. Nucleosides Nucleotides Nucleic Acids. 2011 Dec; 30(12):1011-7.
Score: 0.383
-
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010; 12(2):R63.
Score: 0.342
-
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun; 36(6):1273-82.
Score: 0.317
-
Hyperuricemia and associated diseases. Rheum Dis Clin North Am. 2006 May; 32(2):275-93, v-vi.
Score: 0.260
-
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther. 2006; 8 Suppl 1:S4.
Score: 0.259
-
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005 Dec 08; 353(23):2450-61.
Score: 0.253
-
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial. Arthritis Rheumatol. 2022 09; 74(9):1593-1601.
Score: 0.201
-
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken). 2012 Feb; 64(2):256-61.
Score: 0.097
-
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008 Nov 15; 59(11):1540-8.
Score: 0.078
-
Crystal-induced arthropathies: recent investigative advances. Curr Opin Rheumatol. 2006 May; 18(3):249-55.
Score: 0.065
-
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar; 52(3):916-23.
Score: 0.060
-
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman. Arthritis Rheum. 2003 Jul; 48(7):2036-41.
Score: 0.053